Pharmaceuticals & Drugs
|Market Cap||9,042 Cr||EPS||29.5||High||672|
|Stock P/E||22.5||Net Profit Margin||23.4||Low||658.3|
Eris Lifesciences Price chart
|Market Cap||9,042 Cr||ROE||23.3%|
|P/B Ratio||4.4||Dividend Yield||0.9%|
|Industry P/E||65.5||Book Value||149.5|
About the Company
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.
The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.
Business area of the company
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.
History and milestones
|Parent Organisation||Eris Lifesciences Ltd.||Managing Director||Amit Indubhushan Bakshi|
All values are in Rs Cr
|Company||52 Week||Market Price||P/E Ratio|
Frequently asked questions